Impaired renal function in a rural Ugandan population cohort [version 3; peer review: 1 approved, 1 approved with reservations]

Robert Kalyesubula, Jeffrey P. Hau, Gershim Asiki, Billy Ssebunya, Sylvia Kusemererwa, Janet Seeley, Liam Smeeth, Laurie Tomlinson, Robert Newton

1MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
2Department of Physiology, Makerere University College of Health Sciences, Kampala, Uganda
3Non-Communicable Disease Epidemiology, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
4African Population and Health Research Center, Nairobi, Kenya
5Global Health and Development Department, London School of Hygiene and Tropical Medicine, London, UK
6University of York, York, UK

Abstract

**Background:** Kidney disease is an important cause of morbidity and mortality globally. However, there are limited data on the prevalence of impaired kidney function in sub-Saharan Africa. We aimed to determine the prevalence of reduced kidney function and associated factors in a rural Ugandan population.

**Methods:** We undertook a study of a representative sample of the General Population Cohort in South-western Uganda. We systematically collected data on cardiovascular disease risk factors, anthropometric measurements and blood tests including haemoglobin, HIV, HbA1c and serum creatinine. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi equation, without the race component of the equation.

**Results:** A total of 5,979/6,397 (93.5%) participants had valid creatinine results. The mean age was 39 years (Range:16-103 years) and 3,627 (60.7%) were female. HIV prevalence was 9.7% and about 40% of the population were pre-hypertensive or hypertensive. The mean serum creatinine level was 0.75 mg/dl (95% CI 0.74–0.75), and the average eGFR was 109.3 ml/min/1.73 m² (95% CI 108.8–109.9). The overall prevalence of eGFR <60 ml/min/1.73 m² was 1.64% (98/5,979) (95% CI 1.34–1.99). Additionally, 4,792(80.2%) were classified as normal eGFR (≥90 ml/min/1.73 m²), 1,089(18.2%) as low eGFR (60–89 ml/min/1.73 m²), 91(1.52%) as moderately reduced eGFR (30–59 ml/min/1.73 m²), 4(0.07%) as severely reduced eGFR (15-29 ml/min/1.73 m²), and 3(0.05%) classified...
as having kidney failure (eGFR<15 ml/min/1.73 m²). When age-standardised to the WHO Standard Population the prevalence of eGFR<60 ml/min/1.73 m² was 1.79%. Age above 35 years and the presence of hypertension (OR 2.86, 95% CI 1.15-7.08) and anaemia (OR 2.14, 95% CI 1.12-4.09) were associated with eGFR<60 ml/min/1.73 m².

**Conclusion:** In a systematic survey of people in rural Uganda, we found a substantial proportion had eGFR<60 ml/min/1.73 m². More population based studies are needed to further characterize kidney disease in sub-Saharan Africa.

**Keywords**
Kidney disease, population cohort, epidemiology, prevalence
Introduction

Chronic kidney disease (CKD) is an under-recognized non-communicable disease, associated with a high morbidity and mortality. It is estimated that one in ten people are living with kidney disease worldwide and the prevalence may be higher in low-income countries such as Uganda\(^1,2\). However, as shown in a recent systematic review the quality of data is often poor, frequently using convenience samples in high-risk populations\(^3\). Furthermore, only 2% of the studies included in this review used the CKD-EPI equation for calculation of estimated glomerular filtration rate (eGFR) which, based on limited data, has been found to be the best estimate of population CKD prevalence\(^4\). There is little distinction between impaired renal function and chronic kidney diseases in most of the studies from sub-Saharan Africa where these two are used interchangeably\(^5\). It is thus more appropriate to use impaired renal function rather than CKD when creatinine and albuminuria are measured once with no repeated measure to confirm chronicity. Community-based studies of the prevalence of impaired renal function have shown marked variation in results. Among people living with HIV/AIDS, estimates range from 0.7% in Rakai, Central Uganda, 14.4% in Gulu, Northern Uganda, 26.5% in Zambia to 41.3% in Tanzania\(^6,7,8\). Among HIV-negative populations, estimates range from 2.5% in Wakiso, Central Uganda to 26.5% in Tanzania\(^9\). Hospital-based studies from a National Referral Hospital in Uganda show that most patients with kidney disease are young and have advanced disease by the time of presentation\(^10\). Thus, in sub-Saharan Africa estimates of kidney disease prevalence vary widely depending on the methods used to determine renal function and the population studied, in particular the age distribution\(^11-19\).

Globally, among the known risk factors for CKD are diabetes mellitus, hypertension and infections such as HIV. Hypertension and HIV are important problems in Uganda with hypertension prevalence estimated to be 26.4%\(^20\) and rising among those with HIV-infection\(^12\). However, the prevalence of diabetes mellitus is low compared to high-income countries at 2%\(^21\). Moreover, some studies have also highlighted differences in the prevalence of impaired renal function between urban and rural areas in Africa. A study from Cameroon found the overall prevalence of CKD to be 13.2%: 14.1% and 10.9% among rural and urban dwellers, respectively\(^22\). Late diagnosis, along with limited healthcare leading to poor control of hypertension and diabetes may be possible drivers of a higher prevalence in rural populations.

Therefore, we aimed to determine the prevalence and associations of impaired renal function among a representative sample of a rural area of Uganda, within an existing population cohort using high quality sampling methods.

Methods

Study design and setting

The General Population Cohort (GPC) was established in 1989, by the United Kingdom Medical Research Council and the Uganda Virus Research Institute, in Kalungu District, Southwestern Uganda\(^23\). The cohort was initially established to examine prevalence, incidence, risk factors and trends of infection with HIV in a rural African population. More recently, research activity has broadened to include the epidemiology and genetics of other communicable and of non-communicable diseases, including cancer, cardiovascular disease and diabetes\(^24,25\). In brief, the GPC is a community-based open cohort study of residents of 25 neighbouring villages within one-half of a sub-county, lying about 40 km from Lake Victoria. The population is scattered across the countryside in villages defined by administrative boundaries, with a few concentrated in small trading centres. The population under survey includes approximately 22,000 people, less than half of whom are more than 13 years of age. The cohort is dynamic with new births, deaths and migration reported at each round of follow-up. Data are collected through an annual census, an annual questionnaire and serological survey from 1989–2011 and a biennial questionnaire and serological survey thereafter. Details of sexual behaviour, medical, sociodemographic and geographic factors are recorded. Blood specimens are obtained at each biennial survey. Serum is tested for HIV-1 and the remainder is stored at -80°C. Since 1989, the seroprevalence of HIV has remained relatively stable in this population, with about 8% of participants infected; in recent years, prevalence has risen slightly, with the roll out of antiretroviral therapy and consequent improvements in survival.

All eligible participants were evaluated for the study with an acceptance rate of 98%. A total of 6,397 participants were indentified in the two rounds of the GPC (2011–2012 and 2014–2015) with 5,979 (93.5%) individuals having valid creatinine results. The 418 who did not have valid creatinine did not differ in survival. Data collection

Data collected from the GPC questionnaire regarding sexual behaviour and lifestyle factors were self-reported (Supplementary File 1). Anthropometric measurements and blood tests were performed by trained interviewers/nurses using calibrated instruments and following standard operating procedures. We adapted the World Health Organization (WHO) STEP-wise approach to surveillance questionnaire to obtain socio-demographic
characteristics, lifestyle (diet, tobacco, and alcohol consumption), medical history and biophysical measurements. Blood pressure was measured using a digital sphygmomanometer (Omron M4-1). The participant had to be in a sitting position and the mean of the second and third readings taken at 5-minute intervals was used for analysis. Body weight was measured using the Seca 761 mechanical scales and body height was measured using a stadiometer to the nearest 1 kg and 0.1 cm, respectively. Both scales were calibrated according to manufacturer guidelines weekly.

**Laboratory tests**

Blood tests for haemoglobin, HIV screening, HbA1c, hepatitis B and C viruses, as well as the creatinine level were performed. Venous blood was tested for haemoglobin level using CT -5 Coulter Ac.T 5diff AL (Autoloader) [Beckman Coulter, North America]. HIV testing was performed using an approved national algorithm. Hepatitis B surface antigen, Hepatitis C antibody and creatinine level were tested using a Cobas e 601 Auto Analyzer (Roche Diagnostics, North America). Creatinine was measured using the Jaffe method traceable to an isotopic dilution mass spectrometry method. The MRC/UVRI Entebbe laboratories currently have laboratory accreditation through ISO 15189 of the Kenya Accreditation Service, and are enrolled in external quality control programs for South Africa, America, Australia and the United Kingdom.

**Definitions and classification**

Each participant’s SES was derived from conducting principal component analysis (PCA) using variables relating to household infrastructure and property ownership. Urbanicity score used in this study was derived from a previous study using information from the Round 22 survey. BMI was classified according to WHO categories (weight/height2: kg/m2): underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) and obese (>30.0 kg/m2). Blood pressure (BP) classification was derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic BP greater than 120mmHg but less than 140 mmHg, and a diastolic BP greater than 80 mmHg but less than 90 mmHg. Hypertension was defined as having a diastolic BP greater than or equal to 90 mmHg, systolic BP greater than or equal to 140 mmHg or being on treatment for high BP. Anaemia was defined as having haemoglobin levels less than 130 g/l in men, 120 g/l in non-pregnant women, and 110 g/l in pregnant women. Diabetes mellitus was diagnosed by either having HbA1c >6.5%, through self-reported measures of being previously diagnosed with diabetes, or by current treatment for diabetes.

**Classification of renal function**

The estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi equation, without use of the coefficient for African Americans. Impaired renal function was divided into five categories analogous to CKD stages, based on the National Kidney Foundation guidelines (without including proteinuria) as: normal eGFR (≥90 ml/min/1.73 m2); low eGFR (60–89 ml/min/1.73 m2); moderately reduced eGFR (30–59 ml/min/1.73 m2); severely reduced eGFR (15–29 ml/min/1.73 m2); and kidney failure (eGFR <15 ml/min/1.73 m2). We have used impaired renal function for the study because we did not have a second creatinine after 3 or more months or measures of urinary protein excretion to confirm CKD.

**Statistical analysis**

Baseline characteristics were tabulated stratified by sex. The prevalence of impaired renal function was also age standardised using the WHO world population as the reference.

We used logistic regression to estimate odd ratios (OR), along with its 95% confidence intervals (95% CIs), to identify potential factors independently associated with CKD. A forward stepwise approach was used in developing our multivariable model adjusting for age, sex, and all independent predictors of CKD.

We also conducted a secondary analysis to compare participants with eGFR<60 ml/min/1.73 m2 to those with normal renal function excluding individuals in the low eGFR category. The population attributable fraction (PAF) of impaired renal function was estimated for hypertension, and anaemia using the adjusted odds ratios from the final multivariable model.

All statistical analyses were performed using STATA 13 SE (Stata Corp, Texas, USA).

**Ethical considerations**

All study participants gave written informed consent to participate in the study. The study was approved by Uganda Virus Research Institute Research and Ethics Committee (UVRI-REC) and the Uganda National Council for Science and Technology (UNCST).

**Results**

**Baseline characteristics of study participants**

A total of 6,397 individuals participated in the Round 24 GPC survey in 2014–2015 and 5,979 (93.5%) individuals had valid creatinine test results. The average age of study participants was 39 years (range: 16 years to 103 years), consisting of 3,626 (60.7%) females. The majority of patients had primary-level education (60%). HIV prevalence was 9.7% (males: 8.4%; females: 10.5%) within this study population, and about 40% of the population was classified as pre-hypertensive. The mean serum creatinine level of the study population was 66.3 mmol/l (95% CI 65.4–66.3), and using the CKD-EPI equation, the average eGFR was 109.3 ml/min/1.73 m2 (95% CI 108.8–109.9) (Table 1).

**Prevalence of impaired renal function**

The overall prevalence of eGFR <60 ml/min per 1.73 m2 was 1.6% (95% CI 1.34–1.99). Of the respondents, 4,792 (80.2%) were age and sex adjusted associations with the presence of eGFR <60 ml/min per 1.73 m2 are shown in Supplementary Table 1. In multivariable analysis, older age, hypertension (OR 2.86; 95% CI 1.15-7.08) and anaemia (OR 2.14 ; 95% CI 1.12-4.09) were independently associated with eGFR <60 ml/min per 1.73 m2 (Table 3).
Table 1. Characteristics of participants with creatinine results from Survey round 24 among a general population cohort in rural Uganda (N=5,979).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male, n (%)</th>
<th>Female, n (%)</th>
<th>Total, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age Group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;35</td>
<td>1,033 (43.90)</td>
<td>1,703 (46.97)</td>
<td>2,736 (45.77)</td>
</tr>
<tr>
<td>35–44</td>
<td>460 (19.55)</td>
<td>721 (19.88)</td>
<td>1,181 (19.74)</td>
</tr>
<tr>
<td>45–54</td>
<td>378 (16.02)</td>
<td>507 (13.98)</td>
<td>884 (14.79)</td>
</tr>
<tr>
<td>55–64</td>
<td>244 (10.37)</td>
<td>336 (9.27)</td>
<td>580 (9.70)</td>
</tr>
<tr>
<td>65–74</td>
<td>138 (5.86)</td>
<td>231 (6.37)</td>
<td>369 (6.17)</td>
</tr>
<tr>
<td>75+</td>
<td>101 (4.29)</td>
<td>128 (3.53)</td>
<td>229 (3.83)</td>
</tr>
<tr>
<td><strong>Max Education</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>137 (5.82)</td>
<td>394 (10.87)</td>
<td>531 (8.88)</td>
</tr>
<tr>
<td>Primary</td>
<td>1,488 (63.24)</td>
<td>2,122 (58.52)</td>
<td>3,610 (60.38)</td>
</tr>
<tr>
<td>Secondary</td>
<td>570 (24.21)</td>
<td>946 (26.09)</td>
<td>1,516 (25.35)</td>
</tr>
<tr>
<td>Higher Level</td>
<td>158 (6.71)</td>
<td>164 (4.52)</td>
<td>322 (5.38)</td>
</tr>
<tr>
<td><strong>Currently Married</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>357 (20.62)</td>
<td>1,075 (36.68)</td>
<td>1,432 (30.72)</td>
</tr>
<tr>
<td>Yes</td>
<td>1,373 (79.36)</td>
<td>1,856 (63.32)</td>
<td>3,229 (69.28)</td>
</tr>
<tr>
<td><strong>Urbanicity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quartile 1</td>
<td>513 (28.71)</td>
<td>756 (26.31)</td>
<td>1,259 (27.24)</td>
</tr>
<tr>
<td>Quartile 2</td>
<td>468 (26.19)</td>
<td>733 (25.86)</td>
<td>1,201 (25.98)</td>
</tr>
<tr>
<td>Quartile 3</td>
<td>436 (24.40)</td>
<td>697 (24.59)</td>
<td>1,133 (24.51)</td>
</tr>
<tr>
<td>Quartile 4</td>
<td>370 (20.71)</td>
<td>659 (23.25)</td>
<td>1,029 (22.26)</td>
</tr>
<tr>
<td><strong>SES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower</td>
<td>565 (35.76)</td>
<td>819 (32.79)</td>
<td>1,384 (33.94)</td>
</tr>
<tr>
<td>Middle</td>
<td>521 (33.04)</td>
<td>833 (33.35)</td>
<td>1,354 (33.23)</td>
</tr>
<tr>
<td>Upper</td>
<td>493 (31.20)</td>
<td>846 (33.87)</td>
<td>1,339 (32.83)</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal weight</td>
<td>1,786 (76.47)</td>
<td>2,290 (65.84)</td>
<td>4,076 (70.11)</td>
</tr>
<tr>
<td>Underweight</td>
<td>407 (17.42)</td>
<td>302 (8.68)</td>
<td>709 (12.19)</td>
</tr>
<tr>
<td>Overweight</td>
<td>122 (5.22)</td>
<td>648 (18.63)</td>
<td>770 (13.24)</td>
</tr>
<tr>
<td>Obese</td>
<td>21 (0.90)</td>
<td>238 (6.84)</td>
<td>259 (4.45)</td>
</tr>
<tr>
<td><strong>Blood Pressure</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>668 (40.44)</td>
<td>1,235 (48.82)</td>
<td>1,903 (45.51)</td>
</tr>
<tr>
<td>Pre-Hypertension</td>
<td>719 (43.52)</td>
<td>944 (37.28)</td>
<td>1,663 (39.75)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>265 (16.04)</td>
<td>352 (13.90)</td>
<td>617 (14.75)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male, n (%)</th>
<th>Female, n (%)</th>
<th>Total, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV Status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>2,150 (91.57)</td>
<td>3,242 (89.51)</td>
<td>5,392 (90.32)</td>
</tr>
<tr>
<td>Positive</td>
<td>198 (8.43)</td>
<td>380 (10.49)</td>
<td>578 (9.68)</td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>1,588 (96.48)</td>
<td>2,479 (98.10)</td>
<td>4,067 (97.46)</td>
</tr>
<tr>
<td>Positive</td>
<td>58 (3.52)</td>
<td>48 (1.90)</td>
<td>106 (2.54)</td>
</tr>
<tr>
<td><strong>Hepatitis C</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>1,582 (96.17)</td>
<td>2,439 (96.52)</td>
<td>4,021 (96.38)</td>
</tr>
<tr>
<td>Positive</td>
<td>63 (3.83)</td>
<td>88 (3.48)</td>
<td>151 (3.62)</td>
</tr>
<tr>
<td><strong>Anaemia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>1,078 (86.87)</td>
<td>1,583 (83.40)</td>
<td>2,661 (84.77)</td>
</tr>
<tr>
<td>Positive</td>
<td>163 (13.13)</td>
<td>315 (16.60)</td>
<td>478 (15.23)</td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1,603 (97.74)</td>
<td>2,467 (97.94)</td>
<td>4,070 (97.53)</td>
</tr>
<tr>
<td>Yes</td>
<td>37 (2.26)</td>
<td>52 (2.06)</td>
<td>89 (2.41)</td>
</tr>
<tr>
<td><strong>Current smoking status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No current smoker</td>
<td>1,301 (78.80)</td>
<td>2,478 (97.87)</td>
<td>3,779 (90.34)</td>
</tr>
<tr>
<td>Non-daily smoker</td>
<td>83 (5.03)</td>
<td>17 (0.67)</td>
<td>100 (2.39)</td>
</tr>
<tr>
<td>Daily smoker</td>
<td>267 (16.17)</td>
<td>37 (1.46)</td>
<td>304 (7.27)</td>
</tr>
<tr>
<td><strong>Alcohol consumption</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never drinkers</td>
<td>831 (54.64)</td>
<td>1,589 (69.27)</td>
<td>2,420 (63.43)</td>
</tr>
<tr>
<td>No alcohol in past 30 days</td>
<td>90 (5.92)</td>
<td>250 (10.90)</td>
<td>340 (8.91)</td>
</tr>
<tr>
<td>Alcohol in past 30 days</td>
<td>600 (39.45)</td>
<td>455 (19.83)</td>
<td>1,055 (27.65)</td>
</tr>
</tbody>
</table>

*Variables from a previous round (R22) of the GPC where total number of participants may vary: Urbanicity (n=4,622), SES (n=4,077), Blood Pressure (BP) (n=4,184), Hepatitis B (n=4,173), Hepatitis C (n=4,172), smoking status (n=4,183), alcohol consumption in the last 30 days (n=3,815), and anaemia (n=3,139). Urbanicity score derived from Riha et al. (2014).  
**Socio-economic Score (SES) derived from conducting Principle Component Analysis (PCA) on a statistical software using variables relating to household infrastructure and property ownership Body Mass Index (BMI) Classification according to WHO (weight/height²): kg/m². Underweight (<18.5 kg/m²), Normal weight (18.5–24.9 kg/m²), Overweight (25.0–29.9 kg/m²), Obese (>30.0 kg/m²). BMI classification derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic BP ≥120 mmHg but <140 mmHg, and a diastolic BP ≥90 mmHg but <90 mmHg. Hypertension was defined as having a systolic BP ≥140 mmHg, and a diastolic BP ≥90 mmHg. Anaemia was defined as having hemoglobin levels less than 130 g/L in men, 120 g/L in non-pregnant women, and 110 g/L in pregnant women. Only 2,064 individuals had anaemia results from the R24 of the GPC  
Diabetes was defined as having HbA1C >6.5%, or being previously diagnosed with diabetes, or are currently on treatment for diabetes.  
*Variables in R24 with missing individuals: Currently Married (n=4,661), BMI (n=5,814), HIV (n=5,970)
Prevalence of estimated glomerular filtration rate $<60$ ml/min/1.73 m$^2$ by age group among a rural Ugandan cohort.

Table 2. Mean serum creatinine and categories of estimated glomerular filtration rate (eGFR) in the general population cohort.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurements</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>0.75 (0.74–0.75)</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73m$^2$)</td>
<td></td>
</tr>
<tr>
<td>CKD-EPI equation$^*$</td>
<td>109.3 (108.8–109.9)</td>
</tr>
<tr>
<td>MDRD equation$^*$</td>
<td>106.2 (105.4–107.1)</td>
</tr>
<tr>
<td>Individuals n(%)</td>
<td></td>
</tr>
<tr>
<td>Category of level of eGFR</td>
<td></td>
</tr>
<tr>
<td>Normal eGFR ($\geq$90 ml/min per 1.73 m$^2$)</td>
<td>4,792 (80.15)</td>
</tr>
<tr>
<td>Low eGFR (60–89 ml/min per 1.73 m$^2$)</td>
<td>1,089 (18.21)</td>
</tr>
<tr>
<td>Moderately reduced eGFR (30–59 ml/min per 1.73 m$^2$)</td>
<td>91 (1.52)</td>
</tr>
<tr>
<td>Severely reduced eGFR (15–29 ml/min per 1.73 m$^2$)</td>
<td>4 (0.07)</td>
</tr>
<tr>
<td>Kidney Failure (eGFR &lt;15 ml/min per 1.73 m$^2$)</td>
<td>3 (0.05)</td>
</tr>
</tbody>
</table>

$^*$The CKD-EPI eGFR calculations were used as the primary outcomes in this study; the MDRD equation was used to contrast the difference between the two equations. $^1$The coefficient for black race was omitted while using this equation.

Age and sex adjusted associations of variables with the presence of eGFR of $<90$ ml/min/1.73m$^2$ are shown in Supplementary Table 2. In multivariable analysis, female sex (OR 1.56, 95% CI 1.27-1.93); older age, higher urbanicity score, being overweight or obese; having hypertension (OR 1.60, 95 % CI 1.22-2.11) and HIV-positive status (OR 1.55, 95% CI 1.13-2.04) were associated with impaired kidney function (Supplementary Table 3).

Comparison of participants with eGFR $<60$ ml/min/1.73m$^2$ to those with eGFR $>90$ ml/min/1.73m$^2$ revealed that older age,
hypertension and anaemia were independently associated with impaired renal function (Supplementary Table 4).

The adjusted population attributable fraction of decreased renal function attributable to hypertension and anaemia was 26.4% and 12.8%, respectively.

Discussion
We found a prevalence of eGFR <60 mL/min per 1.73 m² of 1.64% in this predominantly young rural community of Uganda with more than one-fifth of the study participants having eGFR <90 mL/min per 1.73 m². Impaired renal function was strongly associated with age, high blood pressure and anaemia.

Comparing different prevalence estimates of impaired renal function from studies across sub-Saharan Africa is challenging for many reasons. In a meta-analysis of CKD in sub-Saharan Africa by Stanifer et al. the overall prevalence was 13.9% but the majority of the studies were conducted among patients with known risk factors for renal disease such as diabetes mellitus, HIV infection and hypertension. Furthermore, only 2% of the included studies used the CKD-EPI equation for calculation of eGFR although, based on limited data, it has been found to be the best estimate of population CKD prevalence⁴. The age structure of population varies widely between countries in sub-Saharan Africa making standardisation to a reference population crucial for comparisons between regions or countries. In addition, the prevalence of risk factors such as HIV infection vary substantially across and within countries. We found a lower prevalence of eGFR <60 mL/min per 1.73 m² in this rural setting than would be expected according to previous studies⁴. This unexpected finding could be explained by the characteristics of the population under study. Over 66% of our study participants were less than 45 years of age yet CKD prevalence increases with age. The traditional risk factors for CKD like diabetes mellitus, hypertension, obesity, alcohol intake and smoking were low in our population (see Table 1).

We found that older age, hypertension and anaemia were associated with impaired renal function. Age is known to be strongly associated with eGFR⁴,⁵,⁶. Hypertension is both a cause and a consequence of kidney disease, and in this cross-sectional survey it was not possible to tell whether the participants had hypertension as a cause or consequence of the kidney disease. However there has been a rise in reported levels of hypertension in Uganda, from 13.7%⁴ in 1969 to 26.4% in 2015⁷. Anaemia is also often a consequence of kidney disease, or may be due to shared risk-factors such as other chronic diseases. We found that anaemia was associated with kidney disease, even for patients with eGFR <90 mL/min/1.73 m², a level of kidney function at which a direct causal effect would not be anticipated.

We only measured creatinine on one occasion while two results of eGFR <60 mL/min per 1.73 m² more than 3 months apart are required for the formal definition of CKD. This may have led to an overestimate of the prevalence of impaired renal function. However, most large scale epidemiological surveys have also used one measurement of creatinine⁴. In addition, our study was prospectively sampled from well people and are thus likely to be affected by a transient fall in eGFR associated with acute illness. This is in contrast to many studies using routinely collected data to define renal function where misclassification is likely if blood tests are measured during when patients are unwell⁴. Even if we had two measures of creatinine we would not have been able to confidently assert that patients with eGFR <60 mL/min per 1.73 m² had ‘chronic kidney disease’ as the estimating equations are not validated in sub-Saharan Africa and the long-term outcome implications, on which the CKD categorisation was defined, are not yet understood in this setting. From the multivariable analysis hypertension and anaemia are likely manifestations of chronic kidney disease, so it is not unreasonable to presume that impaired kidney function is an estimate of CKD. It is also very difficult to have a repeat creatinine and urinalysis in community studies. More studies are needed to establish the utility of the second creatinine/urinary protein in establishing chronicity of kidney disease. There is

Table 3. Final multivariable model of factors independently associated with estimated glomerular filtration rate <60 ml/min per 1.73m².

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adjusted OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.19 (0.64–2.24)</td>
<td></td>
</tr>
<tr>
<td><strong>Age Group</strong></td>
<td>P=0.001</td>
<td></td>
</tr>
<tr>
<td>&lt;35</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>35–44</td>
<td>0.53 (0.05–5.14)</td>
<td></td>
</tr>
<tr>
<td>45–54</td>
<td>3.49 (0.86–14.09)</td>
<td></td>
</tr>
<tr>
<td>55–64</td>
<td>5.73 (1.47–22.25)</td>
<td></td>
</tr>
<tr>
<td>65–74</td>
<td>12.24 (3.27–45.82)</td>
<td></td>
</tr>
<tr>
<td>75+</td>
<td>29.68 (7.99–110.19)</td>
<td></td>
</tr>
<tr>
<td><strong>Blood Pressure</strong></td>
<td>P=0.05</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Pre-Hypertension</td>
<td>1.92 (0.81–4.57)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.86 (1.15–7.08)</td>
<td></td>
</tr>
<tr>
<td><strong>Anaemia</strong></td>
<td>P=0.02</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>2.14 (1.12–4.09)</td>
<td></td>
</tr>
</tbody>
</table>

*Variables from a previous round (R22) of the GPC where total number of participants may vary: Blood Pressure (n=3,039). Multivariable model adjusted for age, sex and all independent predictors of eGFR <60 ml/min per 1.73 m². OR, odds ratio; 95% CI, 95% confidence interval. Blood pressure classification derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic blood pressure greater than 120 mmHg but less than 140 mmHg, and a diastolic blood pressure greater than 80 mmHg but less than 90 mmHg. Hypertension was defined as having a systolic blood pressure (SBP) greater than or equal to 90 mmHg, diastolic BP greater than or equal to 140 mmHg. Anaemia was defined as having haemoglobin levels less than 130 g/L in men, 120 g/L in non-pregnant women, and 110 g/L in pregnant women. Only 2,064 individuals had anaemia results from the R24 of the GPC.
also need to put this in the context of poorly resourced countries where patients are likely to be lost to follow up. The initial contact may be the only opportunity to diagnose them and put them into formal care with the aim of reducing progression to serious complications.

Factors which have been traditionally associated with kidney disease in high-income countries such as smoking, alcohol intake and obesity were not associated with the presence of eGFR <60 mL/min per 1.73 m$^2$ in this population. This may be because of the low prevalence of these factors in the community, or may suggest that the risk factors for CKD are different in this region. Indeed, other researchers have found that the majority of kidney disease in sub-Saharan Africa is not explained by traditional risk factors.

Study strengths and limitations
This was a large community-based study conducted within a well-characterized population cohort. We used the CKD-Epi equation to determine eGFR, which is thought to be the best estimate of true GFR in sub-Saharan Africa. We measured a wide range of social and anthropometric factors, chronic diseases and biochemical measurements in a structured and validated manner. In addition, our prevalence estimates have been standardized to the WHO population to enable comparability with other studies across the world.

However, there were limitations, including lack of screening for urine abnormalities (proteinuria and hematuria) which could have led us to underestimate the prevalence of kidney disease. Newer classifications of CKD require measurement of proteinuria to define kidney disease. We only measured creatinine on one occasion while two results of eGFR <60 mL/min per 1.73 m$^2$ more than 3 months apart are required for the formal definition of CKD. This may have led to an overestimate of the prevalence of impaired renal function.

Implications of the study
Interventions for end-stage renal disease are currently limited for most countries in sub-Saharan Africa with very poor access to dialysis and kidney transplantation. This study has established a significant prevalence of impaired renal function, highlighting the need to focus efforts on preventive strategies to delay onset and slow progression of renal disease. However, marked uncertainty remains about how best to estimate GFR in black Africans. This highlights the importance of our ongoing prospective study to determine the best way to measure renal function in sub-Saharan Africa: http://blogs.lshtm.ac.uk/ark/.

Conclusions
We found that approximately one in five adults in rural Uganda had abnormal function despite a low prevalence of diabetes and obesity. More population based studies are needed to further characterize kidney disease in sub-Saharan Africa.

Data availability
Owing to data protection concerns, there are restrictions on access to the underlying data. The GPC database contains 25 years of longitudinal data sets on demographics and disease surveillance. All data (census, survey and laboratory) generated through the cohort are stored and curated at the MRC/UVRI and the LSHTM Research Unit. Data access for specific research purposes is possible and has been granted previously. For any data access inquiries, you may contact the director, MRC/UVRI and the LSHTM Research Unit or by email to mrc@mrcuganda.org or the corresponding author.

Grant information
RK is funded by a grant from GlaxoSmithKline Africa Non-Communicable Disease Open Lab (Project Number: 8111) as part of a broader multicenter collaborative study between South Africa, Uganda, Malawi and the London School of Hygiene and Tropical Medicine which is collectively identified as the African Research in Kidney Disease (ARK) Network. LAT is funded by a Wellcome Trust intermediate clinical fellowship (101143/Z/13/Z).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We would like to thank the General Population Cohort team, which helped in the collection of data and implementation of the study and all the participants.

Supplementary material
Supplementary Table 1. Factors associated with estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m$^2$ among a general population cohort from rural Uganda.
Click here to access the data.

Supplementary Table 2. Factors associated with estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m$^2$ among a general population cohort from rural Uganda.
Click here to access the data.

Supplementary Table 3. Final multivariable model of factors independently associated with estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m$^2$ among a general population cohort from rural Uganda.
Click here to access the data.
Supplementary Table 4. Final multivariable model of factors independently associated with CKD comparing individuals with estimated glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m² to individuals with eGFR <60 ml/min per 1.73 m².

Click here to access the data.

Supplementary File 1. GPC questionnaire regarding sexual behaviour and lifestyle factors.

Click here to access the data.

References


Open Peer Review

Current Peer Review Status: ✔️ ?

Version 2

Reviewer Report 17 January 2019

https://doi.org/10.21956/wellcomeopenres.16352.r34526

© 2019 Kilonzo K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kajiru G Kilonzo
Internal Medicine Department, Kilimanjaro Christian Medical Center, Moshi, Tanzania

Thank you for the opportunity to review this article again.

General Comments
A well written article and very relevant problem being questioned. The use of a General Population Cohort which is well documented is an opportunity to follow them up further. Use of the CKD epi formula is a good addition among published data in Africa. This work could be indexed with some additional work.

I still think the article has important information to share to the scientific community even though the disease has not been defined properly. Efforts to define the link between impaired kidney function and CKD which is the assumed disease could be further made. Why is impaired kidney function a poor man’s estimate of chronic kidney disease in a community study? I note that this is somewhat discussed. More is needed to justify using impaired kidney function and CKD interchangeably.

One way of looking at this is from the following argument derived from the authors’ data. From the multivariable analysis hypertension and anaemia are likely manifestations of chronic kidney disease, so it is not unreasonable to presume that impaired kidney function is an estimate of CKD.

The study highlights the importance of determining the best way of estimating CKD from the community. This statement could be more emphasized. This could be coming out as the discussion point instead of a study limitation.

Abstract
Very representative of the work. Include a recommendation from your conclusion if possible.

Introduction
This part explains very clearly the importance of CKD, the unavailability of quality data and the variability of impaired renal function.
- Again, in the flow of thoughts, the transition between CKD and impaired renal function has not been linked.
- The last sentence of the second paragraph “Late diagnosis…….” appears to be an original
idea/conclusion. Rural populations have lower prevalence of CKD. (Stanifer et al., 2015\textsuperscript{1}). This could be included in the discussion as well. Otherwise some justification for doing the study (as stated above) are clear.

**Methods**
As the last statement of the introduction emphasizes on high quality sampling methods, It could be clearer how the authors sampled 5979 individuals from the 22,000 population. What was the sampling method? The population is within a prospective cohort study. Is it not true that the data collected was cross sectional?

**Discussion**
The prevalence found of 1.6% is significantly low compared to the global prevalence of CKD. This needs to be discussed in light of the definitions used. Impaired renal function vs CKD. Remember while you hypothesize that the rural population have more CKD, this cohort has very low levels of decreased eGFR. The strength would be in discussing this.
The second paragraph delineates why the results are not comparable, why not use studies which used the same measure of impaired renal function? Furthermore, the use of MDRD to estimate the eGFR can not explain such a huge difference in prevalence. Again, this needs to come out.

In the risk factor paragraph, the authors mention that the traditional risks are not seen. Is there CKDu?

**Conclusions**
It was not clear from the study why more data on risk factors is needed.

References

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Peritoneal dialysis, Acute Kidney disease, CKD

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 09 May 2019

**Laurie Tomlinson**, LSHTM, London, UK

Dear Professor Kilonzu,
Thank you very much for taking time to review our paper. We believe we have made the necessary changes to highlight the difference between impaired renal function and chronic kidney disease. We have added more details on the selection criteria of the study population and addressed all the comments that were raised by the reviewer making this manuscript much more improved from the second version.
Please find below a detailed response to each of the issues raised.

**General Comments**
A well written article and very relevant problem being questioned. The use of a General Population Cohort which is well documented is an opportunity to follow them up further. Use of the CKD epi formula is a good addition among published data in Africa. This work could be indexed with some additional work.
I still think the article has important information to share to the scientific community even though the disease has not been defined properly. Efforts to define the link between impaired kidney function and CKD which is the assumed disease could be further made. Why is impaired kidney function a poor man’s estimate of chronic kidney disease in a community study? I note that this is somewhat discussed. More is needed to justify using impaired kidney function and CKD interchangeably.
One way of looking at this is from the following argument derived from the authors’ data. From the multivariable analysis hypertension and anaemia are likely manifestations of chronic kidney disease, so it is not unreasonable to presume that impaired kidney function is an estimate of CKD.
The study highlights the importance of determining the best way of estimating CKD from the community. This statement could be more emphasized. This could be coming out as the discussion point instead of a study limitation. Exactly as you have been saying

Response
Thank you for the kind comments. You raise a very important issue on the distinction between impaired renal function and CKD. We have now further made this distinction in our paper. Please see page 7 under the section of definition of renal function.
We have also moved the issue of a single creatinine for community studies to the discussion section and made more suggestions for the same. Please see page 14 under the discussion section.

**Abstract**
Very representative of the work. Include a recommendation from your conclusion if possible.

Response
We have now advocated for more population based studies to characterize CKD. Please see recommendation under the conclusion section.

**Introduction**
This part explains very clearly the importance of CKD, the unavailability of quality data and the variability of impaired renal function.
- Again, in the flow of thoughts, the transition between CKD and impaired renal function has not been linked.
- The last sentence of the second paragraph “Late diagnosis………” appears to be an original idea/conclusion. Rural populations have lower prevalence of CKD. (Stanifer et al., 2015¹). This could be included in the discussion as well.
Otherwise some justification for doing the study (as stated above) are clear.

Response
We have added a sentence to link impaired renal function and CKD. Please see page 4.
We have included the issue of rural vs urban prevalence of CKD in the discussion. Please see page 14 in the discussion section.

Methods
As the last statement of the introduction emphasizes on high quality sampling methods, it could be clearer how the authors sampled 5979 individuals from the 22,000 population. What was the sampling method? The population is within a prospective cohort study. Is it not true that the data collected was cross sectional?

Response
This has been further explained in the methods section.
All eligible participants were evaluated for the study with an acceptance rate of 98%. A total of 6,397 participants were identified in the two rounds the GPC (2011–2012 and 2014–2015 with 5,979 (93.5%) individuals having valid creatinine results. The 418 who did not have valid creatinine did not differ significantly from those selected.
The 22,000 is the general population with only 48% older than 13 years of age. Therefore, the eligible population for the study with 18 years and older was less than 8,000 people. Furthermore, only participants available during the period of the survey are evaluated and included in studies.

Discussion
The prevalence found of 1.6% is significantly low compared to the global prevalence of CKD. This needs to be discussed in light of the definitions used. Impaired renal function vs CKD. Remember while you hypothesize that the rural population have more CKD, this cohort has very low levels of decreased eGFR. The strength would be in discussing this. The second paragraph delineates why the results are not comparable, why not use studies which used the same measure of impaired renal function? This is fair enough. Were there papers in Stanifer that used CKD epi on population samples? Furthermore, the use of MDRD to estimate the eGFR cannot explain such a huge difference in prevalence. Again, this needs to come out.
In the risk factor paragraph, the authors mention that the traditional risks are not seen. Is there CKDu?

Response
Thank you for bringing these comments. We have modified the discussion to explain the lower than expected levels of impaired renal function. We have also cited studies that looked at impaired renal function which is actually most of the studies coming from SSA because they usually only do one measurement of creatinine and or microalbuminuria. In the paper we say: “We found a lower prevalence of of eGFR <60 mL/min per 1.73 m^2 in this rural setting than would be expected according to previous studies." This unexpected finding could be explained by the characteristics of the population under study. Over 66% of our study participants were less than 45 years of age yet CKD prevalence increases with age. The traditional risk factors for CKD like diabetes mellitus, hypertension, obesity, alcohol intake and smoking were quite low in our population (see table 1).”
Regarding the possibility of CKDu, we cannot be certain. Certainly our estimated prevalence is far lower than that seen in hot spots like lowland regions in Sri Lanka, Nicaragua, and El Salvador. Our collaborators in Malawi have found similar urban and rural prevalence, making a disease related to agricultural work unlikely (paper under review). Although we do not know the cause of CKD in our population we cannot be confident that it represents CKDu. This is however a good consideration...
that requires further exploration.

**Conclusions**

It was not clear from the study why more data on risk factors is needed. He is right to point out that this is always a bit of a cop out. Need a stronger finishing sentence.

**Response**

This has been modified accordingly please see the conclusion section.

We found that approximately one in five adults in rural Uganda had abnormal kidney function despite a low prevalence of diabetes and obesity. More population based studies are needed to further characterize kidney disease in SSA.

**Competing Interests:** None

---

**Reviewer Report 04 January 2019**

https://doi.org/10.21956/wellcomeopenres.16352.r34525

© 2019 Feehally J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

John Feehally
Department of Nephrology, Leicester General Hospital, Leicester, UK

The authors have responded very satisfactorily to the reservations I expressed. The term ‘impaired renal function’ is now used rather than CKD since their methodology does not allow formal identification of CKD. The discussion is significantly improved in reviewing the limitations as well as strengths of the study.

Two typos should be corrected:
Discussion: Study Strengths & Limitations, para 2, line 6. The sentence should read: "In addition our study was prospectively sampled from well people and is this unlikely to be affected by any transient falls in eGFR associated with acute illness”
Discussion: Study Strengths & Limitations, para 2, line 8. The word ‘during’ should be deleted. The sentence should read: “….. if blood tests are measured when people are unwell.”

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I am a recently retired UK academic nephrologist with a 15 year experience in leadership of the International Society of Nephrology which has a primary focus on improving kidney care in low and middle income countries. I lead capacity building programs for that society, including education and research training, and have a major focus on the challenges this represents in sub-Saharan Africa.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This well written work has the aim to alert us of the presence of kidney diseases in a rural cohort. Even though the introduction could be built towards the question of the risk factors in view of CKD unknown, the idea is to provide us with a starting point for epidemiological discussion in rural Africa.

The methodology has the strength of measuring serum creatinine using a standardized assay. And CKD Epi formula is an advantage. The main weakness is the use of one serum creatinine which actually brings up an ethical question in this General Population Cohort (1989, UK funded) especially for those found to have CKD. A report on what happened to them would be helpful. And hence the use of impaired renal function would fit more appropriately instead of CKD.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
No

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Peritoneal dialysis, Acute Kidney disease, CKD
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 18 Dec 2018

Laurie Tomlinson, LSHTM, London, UK

Dear Professor Kilonzo,
Many thanks for your review of our paper. You raise very similar concerns to Professor Feehally and we agree with the issues you have raised. We hope that our new draft of the paper fully addresses these concerns. We very much agree about the importance of understanding renal and other outcomes among the cohort we have examined here. This work is underway as part of the ARK study (http://blogs.lshtm.ac.uk/ark/) and we will be able to report on changes in renal function and mortality rates at different levels of renal function when this work is complete.

Competing Interests: None

Reviewer Report 03 December 2018

https://doi.org/10.21956/wellcomeopenres.16198.r34314

© 2018 Feehally J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

John Feehally
Department of Nephrology, Leicester General Hospital, Leicester, UK

This is in many ways a very well-executed population cohort study of adults in rural Uganda, with the aim of identifying chronic kidney disease (CKD) and associated risk factors. The organisational and logistic challenges of such a cohort study in rural sub-Saharan Africa are well understood, and the authors are to be congratulated for their achievement. The methods, result and discussion are all very clearly written.

However the study has one fundamental design flaw. CKD is a chronic condition, and by definition can only be confirmed when serum creatinine is measured, and from that GFR is estimated, on two separate occasions. Prevalence can be misleading when a single measurement is used. The authors themselves recognise this in the final sentence of ‘Study Strengths & Limitations’: “We only measured creatinine on one occasion; two screenings are required for the formal definition of CKD.”

Regrettably a substantial proportion of the CKD epidemiology literature is flawed by reliance on a single measurement of kidney function, and claiming to identify CKD. This is particularly so in studies from low and middle income countries.

The challenge of recalling a study cohort for second sampling is recognised and understood, especially in a low resource setting, such as Uganda. But in the opinion of this reviewer does not justify the report here submitted. While the majority of those identified in this study are likely to have CKD, it is not sound to
report these data as showing the prevalence of CKD, when a fundamental aspect of the epidemiological definition of CKD has not been accounted for.

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? No

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Not applicable

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? No

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I am a recently retired UK academic nephrologist with a 15 year experience in leadership of the International Society of Nephrology which has a primary focus on improving kidney care in low and middle income countries. I lead capacity building programs for that society, including education and research training, and have a major focus on the challenges this represents in sub-Saharan Africa.

I have read this submission. I believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 14 Dec 2018

**Laurie Tomlinson, LSHTM, London, UK**

Dear Professor Feehally,

Many thanks for your helpful comments on the first draft of this paper. While the vast majority of epidemiological surveys are based on one measure of creatinine, we fully agree that this is limited and indeed had tried to make this point. We have now fully revised the paper in line with your suggestions to make our approach and the limitations clear. We have also discussed in more depth the need for better quality research into the prevalence of kidney disease in sub-Saharan Africa in terms of population sampling, creatinine measurement and understanding how best to estimate GFR from creatinine levels in this population. This paper provides the first stage of a large ongoing study to do exactly this: [http://blogs.lshtm.ac.uk/ark/](http://blogs.lshtm.ac.uk/ark/). We hope that this draft will now meet your approval.

**Competing Interests:** No competing interests were disclosed.